Overview

Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia

Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Objectives: To compare the efficacy and safety in Adult patients (≥18 years) diagnosed as essential thrombocythemia treated with the Pegylated Interferon Alfa-2b vs. Interferon Alfa. Study Design: A prospective, open-label, multicenter, randomized controlled clinical trial.
Phase:
Phase 4
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b